Skip to main content

The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension

Focus on Recent Studies

American Journal of Cardiovascular Drugs volume 10, pages 315–320 (2010)Cite this article

Abstract

Hypertension remains a significant health problem, affecting approximately 30% of the US population. Of these, only 36.8% have BP controlled to recommended levels of <140/90 mmHg for uncomplicated hypertension and <130/80 mmHg for patients with diabetes mellitus or renal disease. For those with uncontrolled hypertension, the risk of diabetes, renal disease, stroke, and cardiovascular disease is increased. Therapeutic options for the treatment of hypertension include several major classes of drugs: diuretics, ß-adrenoceptor antagonists (ß-blockers), ACE inhibitors, angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), renin inhibitors, calcium channel blockers, and central sympatholytics, alone or in combination. Guidelines recommend thiazide diuretics as preferred first-line monotherapy. However, only 50% of patients will respond adequately to this therapy and the rest will require two or more antihypertensive agents to achieve BP goals. Clinical evidence demonstrates that some drugs have advantages when used in combination rather than as monotherapy. Drugs that block the renin-angiotensin-aldosterone system not only provide BP control but may also provide vascular protection and are metabolically neutral. This is a concise review of the safety and efficacy of ARBs in combination with amlodipine for the treatment of hypertension, with focus on the telmisartan-amlodipine combination. A MEDLINE search of the English literature from 2006 to 2009 of amlodipine in combination with ARBs revealed six publications, which are included in this review.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1

References

  1. Rosamond W, Flegal K, Friday G, et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69–171.

    PubMed  Article  Google Scholar 

  2. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007; 49: 69–75.

    PubMed  Article  CAS  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.

    PubMed  Article  CAS  Google Scholar 

  4. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477–86.

    PubMed  Article  CAS  Google Scholar 

  5. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension: cardiovascular risk factors and their effects on the decision to treat hypertension. Evidence based review. BMJ 2001; 322: 977–80.

    PubMed  Article  CAS  Google Scholar 

  6. Lewington S, Clarke R, Qizilbash N, et al., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.

    PubMed  Article  Google Scholar 

  7. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008; 28: 713–34.

    PubMed  Article  CAS  Google Scholar 

  8. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969–78.

    PubMed  Article  CAS  Google Scholar 

  9. Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. Drugs Today 2008; 44: 443–53.

    PubMed  Article  CAS  Google Scholar 

  10. Chrysant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich) 2008; 10:716–22.

    Article  CAS  Google Scholar 

  11. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007; 21: 220–4.

    PubMed  CAS  Google Scholar 

  12. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens 2001; 14: 978–9.

    PubMed  Article  CAS  Google Scholar 

  13. Lacourcière Y. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99–103.

    PubMed  Google Scholar 

  14. Dicpinigaitis P. Angiotensin-converting enzyme inhibitor-induced cough. Chest 2006; 129 Suppl. 1: 1695–735.

    Google Scholar 

  15. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–80.

    PubMed  Article  CAS  Google Scholar 

  16. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.

    PubMed  Article  CAS  Google Scholar 

  17. Ichihara A, Kaneshiro Y, Sakoda Littlejohn III TW, et al. Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol 2007; 49: 161–6.

    PubMed  Article  CAS  Google Scholar 

  18. Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007; 29: 2667–76.

    PubMed  Article  CAS  Google Scholar 

  19. Littlejohn III TW, Majul CR, Olvera R, et al., on behalf of the study investigators. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11: 1–7.

    Article  Google Scholar 

  20. Littlejohn III TW, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4×4 factorial study. Postgrad Med 2009; 121: 5–14.

    PubMed  Article  Google Scholar 

  21. Littlejohn III T, Majul CR, Oigman W, et al. Combination therapies of telmisartan and amlodipine are effective at lowering 24 hour BP: findings on an ABPM substudy in hypertensive patients [abstract P-50]. J Clin Hypertens (Greenwich) 2008; 10 Suppl. A: A26.

    Google Scholar 

  22. Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 2005; 19: 173–83.

    PubMed  Article  CAS  Google Scholar 

  23. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–7.

    PubMed  Article  CAS  Google Scholar 

  24. ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.

    Article  Google Scholar 

  25. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) Study. Circulation 2006; 113: 1213–25.

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Writing and editorial assistance was provided by Michelle S. Olsher, PhD, of Publication CONNEXION (Newtown, PA, USA), which was contracted by BIPI for these services. The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors, was fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development. The author has received research grants and serves as a consultant to BIPI, Daiichi-Sankyo Pharma and Novartis Pharmaceuticals.

Author information

Affiliations

  1. Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, 5850 West Wilshire Boulevard, Oklahoma City, Oklahoma, 73132-4904, USA

    Steven G. Chrysant MD, PhD

Authors
  1. Steven G. Chrysant MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven G. Chrysant MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chrysant, S.G. The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension. Am J Cardiovasc Drugs 10, 315–320 (2010). https://doi.org/10.2165/11538850-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11538850-000000000-00000

Keywords

  • Amlodipine
  • Valsartan
  • Telmisartan
  • Little Square Mean
  • Olmesartan